These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 12572660)

  • 1. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies.
    Yang S; Beerahee M
    Eur J Clin Pharmacol; 2011 Mar; 67(3):225-33. PubMed ID: 21125264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
    Mentré F; Dubruc C; Thénot JP
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):299-319. PubMed ID: 11468942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal population designs for PK models with serial sampling.
    Gagnon R; Leonov S
    J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental design and efficient parameter estimation in population pharmacokinetics.
    al-Banna MK; Kelman AW; Whiting B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):347-60. PubMed ID: 2231324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
    Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
    Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size computations for PK/PD population models.
    Kang D; Schwartz JB; Verotta D
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):685-701. PubMed ID: 16284914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.
    Marathe A; Van Wart S; Mager DE
    J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):223-35. PubMed ID: 21165681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
    Chenel M; Bouzom F; Aarons L; Ogungbenro K
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):635-59. PubMed ID: 19130188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.